{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-173803","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2023-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.657755+00:00","generated_at":"2026-06-13T18:04:16.058987+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Seres stockholders approve increase in authorized shares from 200M to 240M at annual meeting","bullets":["All three Class II director nominees elected: Berenson, Kender, and Fraser.","Amendment to increase authorized common shares to 240M approved with 98.4% of votes cast in favor.","Ratification of PwC as auditor for FY2023 approved with 99.8% of votes cast in favor.","Advisory vote on executive compensation passed with approximately 99.4% of votes cast in favor."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-173803","json":"https://secwatch.observer/filing/0001193125-23-173803.json","markdown":"https://secwatch.observer/filing/0001193125-23-173803.md","text":"https://secwatch.observer/filing/0001193125-23-173803.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523173803/0001193125-23-173803-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523173803/d518244d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T18:04:16.058987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}